Prostate Cancer

Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.

The combination of olaparib and abiraterone acetate resulted in a postponement of disease progression and enhanced outcomes for individuals with mutations in BRCA, ATM, and CDK12 in metastatic castration-resistant prostate cancer.

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Prior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.

While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

The phase 1/2 CaRe PC trial evaluating INKmune, a biologic therapy, in male patients with metastatic castration-resistant prostate cancer has dosed its first patient.

No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.

A patient with prostate cancer in the SECuRE trial treated with 2 cycles of 67Cu-SAR-bisPSMA at the 8GBq dose level has achieved undetectable prostate specific antigen levels.

In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.

In an interview with Peers & Perspectives in Oncology, Rana McKay, MD, explains how an AI model can affect the disparities faced by racial minority groups and the wider adoption of AI in the prostate cancer space.

Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.

In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.

In a subgroup analysis of the phase 3 EMBARK study, enzalutamide alone or with leuprolide acetate improved metastatic-free survival in men with high-risk prostate cancer following radiotherapy.

The investigational agent is undergoing evaluation in a phase 1/2 trial for the treatment of relapsed or refractory metastatic castration-resistant prostate cancer resistant to androgen receptor pathway inhibitors.